Prophylactic Tocilizumab Reduces the Incidence of Cytokine Release Syndrome in Relapsed/refractory Myeloma Patients Treated with Teclistamab: Implications for Outpatient Step-up Dosing
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Lancman G, Song K, White D, Crosbie T, Sharif I, Emond M Front Oncol. 2024; 14:1446995.
PMID: 39659785 PMC: 11628543. DOI: 10.3389/fonc.2024.1446995.
References
1.
Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A
. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024; 38(2):365-371.
PMC: 10844072.
DOI: 10.1038/s41375-024-02154-5.
View
2.
Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A
. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505.
PMC: 10587778.
DOI: 10.1056/NEJMoa2203478.
View
3.
Martin T, Mateos M, Nooka A, Banerjee A, Kobos R, Pei L
. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer. 2023; 129(13):2035-2046.
DOI: 10.1002/cncr.34756.
View
4.
Banerjee R, Marsal J, Huang C, Lo M, Thiruvengadam S, Kennedy V
. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021; 27(6):477.e1-477.e7.
DOI: 10.1016/j.jtct.2021.03.004.
View
5.
Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G
. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study. Clin Microbiol Infect. 2024; 30(6):764-771.
DOI: 10.1016/j.cmi.2024.02.023.
View